Buy your textbooks here

Free 920-106 Text Books of Killexams.com | study guide | Braindumps | Study Guides | Textbook

Latest Pass4sure PDF Dumps of 920-106 examcollection - Pass4sure 920-106 Q&A - practice questions - VCE - examcollection and 920-106 Actual Questions - study guide - Study Guides | Textbook

Pass4sure 920-106 dumps | Killexams.com 920-106 actual questions | https://www.textbookw.com/


Killexams.com 920-106 Dumps and actual Questions

100% actual Questions - Exam Pass Guarantee with tall Marks - Just Memorize the Answers



920-106 exam Dumps Source : NNCSS SYMPOSIUM call CENTER

Test Code : 920-106
Test cognomen : NNCSS SYMPOSIUM call CENTER
Vendor cognomen : Nortel
: 90 actual Questions

Nice to hear that actual test questions of 920-106 exam are available.
I believe earned higher scores in 920-106 certification with the profit of quite inexpensive products. I got 920-106 exam engine to find rid of arduous standards of this certification. I had sold 920-106 exam braindump to believe splendid grades within the certification. It cease up pinnacle preference due to the fact the ones merchandise are designed in line with my brain-set. It helped me to find read in fifteen days and after this brief time I had scored specific with the profit of these practical merchandise consequently im writing to mention manner to total of you in your top class services.


it's miles unbelieveable, but 920-106 present day dumps are availabe right here.
Today I am very delighted because I believe got a very tall score in my 920-106 exam. I couldnt believe I would live able to effect it but this killexams.com made me believe otherwise. The online educators are doing their job very well and I salute them for their dedication and devotion.


No dissipate of time on searhching internet! organize exact source of 920-106 .
I moreover had a splendid revel in with this training set, which led me to passing the 920-106 exam with over ninety eight%. The questions are actual and valid, and the exam simulator is a tremendous/guidance device, despite the fact that you are no longer planning on taking the exam and sincerely want to expand your horizons and enlarge your knowledge. i believe given mine to a pal, who besides works on this zone but clearly received her CCNA. What I imply is its a splendid reading device for absolutely everyone. And if you blueprint to purchase the 920-106 exam, this is a stairway to achievement :)


Take total gain state-of-the-art 920-106 actual examination and find licensed.
Going thru killexams.com has arrive to live a addiction whilst exam 920-106 comes. And with test springing up in pretty a total lot 6 days changed into getting extra critical. But with subjects I want a few reference manual to wobble occasionally in order that i would find better help. Manner to killexams.com their that made it total smooth to find the subjectsinterior your head easily which would in any other case might live no longer viable. And its far total because of killexams.com products that I controlled to gain 980 in my exam. Thats the highest marks in my beauty.


simply try those modern-day dumps and achievement is yours.
Knowing thoroughly about my time constraint, commenced out trying to find an spotless artery out before the 920-106 exam. After a protracted searh, placed the question and answers via artery of killexams.com which without a doubt made my day. Offering total probably questions with their quick and pointed solutions helped hold near subjects in a brief time and felt delighted to secure actual marks inside the exam. The materials besides are spotless to memorise. I am inspired and satiated with my results.


much less effort, fanciful expertise, assured success.
I was 2 weeks short of my 920-106 exam and my preparation was not total done as my 920-106 books got burnt in fire incident at my place. total I thought at that time was to quit the option of giving the paper as I didnt believe any resource to prepare from. Then I opted for killexams.com and I soundless am in a situation of shock that I cleared my 920-106 exam. With the free demo of killexams.com, I was able to grasp things easily.


Did you attempted this outstanding supply cutting-edge 920-106 dumps.
killexams.com works! I passed this exam ultimate tumble and at that time over 90% of the questions were absolutely valid. They are highly likely to soundless live telling as killexams.com cares to update their materials frequently. killexams.com is a much organization which has helped me more than once. I am a regular, so hoping for discount for my next bundle!


Is there 920-106 exam original sayllabus?
I just bought this 920-106 braindump, as soon as I heard that killexams.com has the updates. Its genuine, they believe covered total original areas, and the exam appears very fresh. Given the current update, their rotate round time and profit is top notch.


actual 920-106 questions and accurate solutions! It justify the charge.
because of 920-106 certificates you purchased many possibilities for security specialists progress on your career. I wanted to progress my vocation in information protection and desired to grow to live certified as a 920-106. if so I decided to purchase profit from killexams.com and commenced my 920-106 exam training through 920-106 exam cram. 920-106 exam cram made 920-106 certificates research smooth to me and helped me to obtain my desires effortlessly. Now im able to yell without hesitation, without this internet site I in no artery passed my 920-106 exam in first strive.


How much does it cost 920-106 qustions bank with actual dumps
Yes, the questions and answers could live very useful and i insinuate it to total people who wants to purchase those checks. Congrats on a process nicely view out and completed. I cleared my 920-106 tests.


Nortel NNCSS SYMPOSIUM call CENTER

VoIP certification tracks - Nortel's back certifications | killexams.com actual Questions and Pass4sure dumps

As outlined in a outdated tip, companies are implementing IP telephony more commonly on their facts infrastructures. The accelerated deployment has created a exigency for certified IP telephony engineers to deliver proven, most beneficial-of-breed expertise.

The IP telephony certifications Nortel at present presents are divided into four classes: pilot specialist, Design expert, back skilled, and Design skilled. This tip discusses the Nortel back music.

assist specialist

The pilot professional certifications are intended to demonstrate an individual's means to do into effect, operate, and troubleshoot a Nortel Networks IP Telephony answer. The back expert certification reflects a candidate with three to six months of event that can deal with pursuits technical issues of a common Nortel IP Telephony answer.

NNCSS - VoIP Succession BCM 3.0

This certification checks the skill to do into effect, function, and troubleshoot the company Communications supervisor three.0. This certification covers hardware, beginning-up, facts and voice networking, applications, and troubleshooting the BCM. To flood the certification, two checks exigency to live successfully completed: know-how requisites and Protocols for IP Telephony options, and Succession BCM three.0. The technology necessities and Protocols for IP Telephony solutions exam is an silhouette of convergence technologies.

NNCSS - CallPilot Rls. 2.0

This certification exams the means to do in force, function, and troubleshoot the VoIP CallPilot 2.0. This certification covers hardware, administration, interoperability with Meridian 1 switches, and security of a lone website CallPilot system. To flood the certification, two tests must live successfully achieved: Meridian Database and CallPilot 2.0.

NNCSS - Symposium cognomen middle Server or Symposium cognomen seat Server installation and protection

These two certifications peek at various the skill to implement, operate, and troubleshoot the Symposium cognomen seat Server. both certifications cover hardware, utility installing, administration, and protection of Symposium call core Server 4.2, Symposium web client 4.0, and Symposium categorical three.0. besides the fact that children, the Symposium call seat Server certification besides tests the architecture, customized configuration and integration of the server. To pass either of those certifications, one exam believe to live efficiently achieved: Symposium call seat or Symposium call core installation and maintenance, respectively.

NNCSS - Symposium call seat TAPI/Agent or call seat TAPI/Agent installing and preservation

These two certifications verify the capacity to do in force, operate, and troubleshoot the Symposium cognomen seat TAPI/Agent. each certifications cover hardware, software setting up, administration, and renovation of Symposium TAPI 2.three and Symposium Agent 2.three. however, the Symposium call seat TAPI/Agent certification besides checks the structure, integration, and custom configuration of the TAPI/Agent. To wobble both of those certifications, one examination must live efficaciously completed: Symposium call middle TAPI/Agent or Symposium call core TAPI/Agent Inst/leading, respectively.

NNCSS - Symposium specific call core or Symposium express cognomen middle installation and renovation

These certifications examine the capacity to enforce, function, and troubleshoot the Symposium specific cognomen middle. both certifications cowl hardware, utility installing, administration, and protection of Symposium express call seat four.2. despite the fact, the Symposium categorical call seat certification besides checks the structure and integration of the cognomen middle. To flood both of the certifications, one examination ought to live efficiently accomplished: Symposium categorical call seat or Symposium categorical call seat Inst and Maint respectively.

NNCSS - VoIP Multimedia communique Server (MCS) 5100 2.0

This certification tests the capability to implement, operate, and troubleshoot the VoIP Multimedia verbal exchange Server (MCS) 5100 2.0. This certification covers setting up of the hardware and application, configuration, preservation, and administration of the Multimedia communication Server (MCS) 5100 2.0. To wobble the certification, two assessments must live efficiently achieved: expertise standards and Protocols for IP Telephony solutions, and VoIP Multimedia verbal exchange Server (MCS) 5100 2.0. The know-how specifications and Protocols for IP Telephony options examination is an overview of convergence technologies.

NNCSS - VoIP Succession 1000/1000M Rls. 3.0 DB Administrator

This certification checks the potential to preserve and troubleshoot the VoIP Succession 1000/1000M Rls. three.0 DB Administrator. This certification covers the structure, configuration, upkeep, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. 3.0 the exhaust of simple Alternate Route alternative (BARS) and network Alternate Route selection (NARS). To circulate the certification, two tests exigency to live successfully completed: expertise requisites and Protocols for IP Telephony solutions, and Succession a thousand/1000M Rls. 3.0 DB Administrator.

NNCSS - VoIP Succession one thousand/1000M Rls. three.0 setting up and upkeep

This certification exams the capacity to set up, configure, and maintain the VoIP Succession 1000/1000M Rls. 3.0. This certification covers the setting up, structure, configuration, preservation, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. three.0, cyber web Telephones i2xxx, and Optivity Telephony manager (OTM) 2.1. To circulate the certification, three tests must live efficaciously achieved: know-how specifications and Protocols for IP Telephony solutions, and Succession 1000/1000M Rls. 3.0 for Technicians, and Succession 1000/1000M Rls. three.0.

support professional

The aid expert certifications build on the specialist's expertise by demonstrating their capacity to do in force, operate, and troubleshoot an advanced Nortel Networks IP Telephony solution. The profit professional certifications reflect a candidate with six to twelve months of fingers-on journey with the means to lead or aid intermediate-level personnel to preserve intricate Nortel IP Telephony solutions.

NNCSE - CallPilot 2.0 Unified Messaging options

This certification assessments the capacity to enforce, operate, troubleshoot and optimize the VoIP CallPilot Unified Messaging solution 2.0. This certification covers the installing, administration, interoperability, security, help techniques and feature usage for a multi web site CallPilot system. To pass the certification, the candidate exigency to first gain their NNCSS - CallPilot Rls. 2.0. consequently, the CallPilot 2.0 Unified Messaging solutions believe to live efficaciously completed to acquire this certification.

NNCSE - Contact middle

This certification checks the potential to do into effect, operate, troubleshoot and optimize the Contact seat products. This certification covers the candidate's capabilities on the Symposium call middle Server (SCCS)/Symposium express call middle/Symposium net customer, Symposium TAPI service provider (TAPI SP), Symposium Agent, and the Symposium net seat Portal. To circulate the certification, the candidate ought to first acquire their NNCSS - Symposium cognomen seat Server and the NNCSS - Symposium call seat TAPI/Agent certification. in consequence, the Contact middle examination believe to live correctly accomplished to harvest this certification.

NNCSE - IP Convergence Succession 1000/1000M Rls. 3.0

This certification checks the means to deploy, configure, retain, and optimize the VoIP Succession 1000/1000M Rls. 3.0. This certification covers the configuration, succession department office (BO), remote workplace, operation, and Meridian 1 to Succession 1000M three.0 migration procedures for the Succession a thousand/1000M Rls. 3.0, web Telephones i2xxx, faraway office 91xx, and Optivity Telephony manager (OTM) 2.1. To pass the certification, the candidate believe to first obtain their NNCSS - VoIP Succession CSE 1000 Rls. 2.0 or the VoIP Succession 1000/1000M Rls. 3.0 installing & maintenance certification. as a result, an extra greater problematic version of the Succession 1000/1000M Rls. three.0 examination should live efficaciously achieved to achieve this certification.

within the IT trade, certifications are a artery to validate an individual's odds within a exact area. The above Nortel IP Telephony certifications are probably the most rig that may display the capabilities of an IP Telephony assist professional. These certifications couldn't substitute years of industry event, however they effect deliver the foundation to back and maneuver Nortel Voice over IP solutions.

The next tip will talk about Nortel's Design IP Telephony certification music.

Richard Parsons (CCIE#5719) is a manager of skilled capabilities for Callisma Inc., a totally owned subsidiary of SBC. He has constructed a superb groundwork in networking ideas, advanced troubleshooting, and monitoring in areas akin to optical, ATM, VoIP, routed, routing, and storage infrastructures. loaded resides in Atlanta GA, and is a graduate of Clemson institution. His inheritance includes senior and predominant consulting positions at international network features, Lucent, and Callisma.


Bel Fuse (BELFB) this tumble 2018 revenue conference call Transcript | killexams.com actual Questions and Pass4sure dumps

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

picture source: The Motley fool.

Bel Fuse (NASDAQ:BELFB)this autumn 2018 earnings convention CallFeb. 21, 2019 11:00 a.m. ET

Contents:
  • organized Remarks
  • Questions and solutions
  • name participants
  • organized Remarks:

    Operator

    first rate day, and welcome to the Bel Fuse Inc. fourth quarter and full-year 2018 results conference name. modern day convention is being recorded. at present, i want to point to the convention over to Mr.

    Dan Bernstein, president and chief executive officer. gratify retract ahead, sir.

    Dan Bernstein -- President and Chief govt Officer

    thank you, Allison. becoming a member of me on the cognomen nowadays is Craig Brosious, their vice president of Finance; and Lynn Hutkin, their director of fiscal reporting. earlier than they start the call, i might relish to query Lynn to wobble over the secure harbor remark. Lynn?

    Lynn Hutkin -- Director of fiscal Reporting

    thank you, Dan. decent morning, everybody. before they start, i might relish to read here secure harbor statement. except for historic suggestions contained on this call, the concerns discussed on this cognomen corresponding to statements related to expected increase from the business's distribution channel, the results of the ERP system implementation and different high-quality business and increase traits are forward-searching statements as described below the inner most Securities Litigation Reform Act of 1995 that involves dangers and uncertainties.

    exact effects could fluctuate materially from those projections. among the factors that might trigger genuine consequences to vary materially from such statements are: the market considerations facing their purchasers; the continuing viability of sectors that count on their products; the outcomes of company and economic conditions; difficulties associated with integrating currently obtained agencies; means and supply constraints or difficulties; product building, commercialization or technological difficulties; the regulatory trade ambiance; dangers associated with foreign currency; uncertainties associated with prison proceedings; the market's acceptance of the business's original items and competitive responses to these original products; the influence of alterations to U.S. change and tariff policies; and the risk elements exact sometimes within the company's SEC stories. In smooth of the hazards and uncertainties, there may besides live no assurance that any forward-looking statement will, in fact, point to to live proper.

    We undertake no obligation to update or revise any ahead-looking statements. They may additionally besides talk about non-GAAP effects throughout this call and reconciliations of their GAAP consequences to non-GAAP effects were protected in their liberate. And simply earlier than turning the cognomen back to Dan, I simply desired to supply each person a heads up that their EBITDA reconciliation table in their usual release became fallacious. there were errors in that desk and a brand original release is popping out.

    So gratify boot that preliminary desk. So it truly is the third table, which is on web page 7 of the liberate.

    Dan Bernstein -- President and Chief govt Officer

    thanks, Lynn. earlier than going throughout the financials, i want to provide a short update on how the companies did from an operational standpoint this quarter and what they behold going ahead. usual, we're very completely satisfied that they closed the 12 months with a different stalwart quarter, bringing their 2018 sales to $548 million, their larger revenue year for the understanding that 2015. extra importantly, their net income for the year of $21 million become the highest in over a decade.

    revenue total the artery through the fourth quarter were $142.7 million, up 19% from the fourth quarter of 2017 with double-digit growth in each and every of the 3 leading product lines. Their backlog of orders remained mighty at $171.2 million at December 31, 2018, a climb of 17% from a 12 months in the past. The enhance in backlog is besides considered across every of their main product companies, which is a first-rate barometer for different future increase. and searching via at the complete 12 months.

    Our Magnetic solutions neighborhood closed the 12 months with $24.4 million enhance in sales over 2017 stages led by tall demand for their built-in connector modules that are used in next-technology switching functions. revenue of their signal Transformer items believe been additionally potent right through 2018 as original courses with clinical and industrial purposes moved into complete production. they now believe besides increased the presence of their magnetic items via their distribution channels, which add to the 12 months-over-12 months sales growth. The backlog of orders from magnetic items grew by artery of $9.7 million or 28% enhance for the understanding that the 2017 yr-end.

    Our Connectivity solutions neighborhood had yr-over-year revenue increase of $sixteen.four million. Their Cinch enterprise expanded profits via $8.2 million compared to 2017 led via mighty demand for optical and copper products utilized in encryption, communication and threat detection radar applications. Their Stewart passive connectors additionally saw boost in income of $8.2 million from 2017 as better pecuniary conditions in the pile business led to tall demand for their premise wiring customs throughout the year. The Cinch and Stewart enterprise besides profit from wonderful increase in earnings through their distribution channel in 2018.

    average, the backlog of orders for their Connectivity products grew by using $7.8 million, or 16%, in view that 2017 12 months-conclusion stages. Their power options and insurance policy community had a turnaround yr as revenue boom of $15.8 million from 2017 led this community to its first 12 months of sales increase when you reckon that 2015. with the exception of the consequences of their NPS divestiture, sales for this group were up $21 million or 14% from closing 12 months, pushed by artery of continued demand for their power supplies in diversity of information core functions. sales of their DC to DC and circuit insurance policy products besides grew in 2018, offset by using a decline favorite for their custom modules.

    The backlog of their orders for their vigour solutions and insurance policy community is up $7.1 million or eleven% from 2017 yr-conclusion levels. From a profitability standpoint, overseas trade first-rate points and a first-rate adjustment draw the transition tax out to mitigate the larger labor and fabric charges that impacted their bottom line this yr. They proceed to hang pricing company as they work through their higher cost stock on end. concerning the tariffs that had been implemented in 2018, they assess that about 10% of their consolidated annual revenues are at the second impacted.

    At this element, the bulk of these charges believe been handed along to their customers in the form of invoice can charge. They proceed to monitor the situation carefully as they artery the tentative March 1 time restrict for the U.S. accomplishing a pretty first-rate cope with China in total event extra increases on existing tariffs. typical, they remain cautiously confident with the continued income boom and profitabilities as they enter 2019.

    And with that, i would flip it over to Craig to quicken in the course of the fiscal replace.

    Craig Brosious -- vice president of Finance

    Thanks, Dan. To supply a quick recap on income. revenue during the fourth quarter were $142.7 million. through geographic segment, North america earnings believe been $70.3 million, Asia income were $49.1 million and Europe believe been $23.3 million.

    with the aid of product neighborhood, Connectivity solutions income had been $46.four million, Magnetic solutions income were $forty eight.6 million and vigour options and insurance blueprint revenue were $47.7 million. raw profit margin expanded to 21.3% in the fourth quarter of 2018 as in comparison with 18.5% within the fourth quarter of 2017 as incremental earnings in 2018 ended in more suitable fastened can impregnate absorption offsetting larger labor expenses total over the yr. moreover, their raw earnings margin total through the fourth quarter of 2017 believe been impacted through inventory-related costs totaling $2 million in connection with keeping their stock on the lower can impregnate or net realizable cost. Their selling, commonplace and administrative expenses were $22.2 million or 15.6% of income as in comparison with $21.1 million or 17.6% of income in the fourth quarter of 2017.

    while the increase in SG&A costs total the artery through the 2018 length $900,000 pertains to a decline in market expense of their COLI policies, which changed into in accordance with the timehonored inventory market recreation during the fourth quarter of 2018. they now believe already began to peer this transpose in 2019. different offsetting components that affected that the variance in the fourth-quarter durations had been better legal and expert charges of $800,000 offset by using a lessen in unhealthy debt expense of $500,000 and a discount in depreciation and amortization of $four hundred,000. On a go-ahead groundwork, they might predict SG&A to quicken between $20 million and $21 million per quarter within the proximate time period, barring any huge fluctuations in foreign currency echange.

    because of these factors, they generated earnings from operations of $8 million in the fourth quarter of 2018 as in comparison to $1 million within the fourth quarter of 2017. pastime expense changed into -- i'm sorry, $1.4 million in the fourth quarter of 2018, down $900,000 from the identical duration closing yr. in case you hold in mind, they refinanced their credit agreement in the fourth quarter of 2017, which ended in an acceleration of deferred financing cost amortization of $1 million during the remaining year's fourth quarter. Their provision for profits taxes became $2.four million for the fourth quarter of 2018 compared to $19.2 million total through final year's fourth quarter.

    the supply for revenue taxes right through the fourth quarter of 2018 was unfavorably impacted via taxes on international salary, the GILTI tax, partially offset by a dwindle within the U.S. tax expense from 35% to 21% in 2018. the availability for revenue taxes in 2017 era included an $18 million impact from the U.S. Tax Cuts and Jobs Act, which become enacted on December 22, 2017.

    profits per partake for category a common shares was $0.31 per partake in the fourth quarter of 2018 as compared with a loss of $1.sixty six per partake in the fourth quarter of 2017. earnings per partake for class B generic shares was $0.33 per partake within the fourth quarter of 2018 as compared with the want of $1.seventy four per partake in the fourth quarter of 2017. On a non-GAAP groundwork, which excludes certain peculiar and different nonrecurring items, EPS for category A shares become $0.37 per partake in the fourth quarter of 2018 as compared with the loss of $0.09 per partake in the fourth quarter of 2017. On a non-GAAP groundwork, EPS for class B shares turned into $0.39 per partake in the fourth quarter of 2018 as in comparison with a want of $0.10 per partake within the fourth quarter of 2017.

    And now i would relish to retract through some stability sheet and cash circulation gadgets. Their money and cash equivalents equilibrium at December 31, 2018, changed into $fifty three.9 million, a lessen of $15.4 million from December 31, 2017. right through 2018, they made payments of $9 million towards their fanciful debt steadiness. They besides used cash for capital charges of $11.6 million, dividend funds of $3.3 million and hobby funds of $four.8 million.

    money owed receivable were $ninety one.9 million at December 31, 2018 as compared with $78.8 million at December 31, 2017. Days income striking believe been 59 days at December 31, 2018, compared to 60 days at December 31, 2017. The boost in debts receivable stability changed into generally because of the bigger revenue volume within the fourth quarter of 2018 as compared to the fourth quarter of 2017. Inventories were $120.1 million at December 31, 2018, up $12.three million from December 31, 2017.

    In January of 2018, they adopted the original income cognizance regular, which hastens the timing during which they earnings become identified and the corresponding liberate of comprehensive items from their stock equilibrium concerning items held at customer control hubs. except for the results of this adoption, their stock stability would believe elevated by $23.4 million from December 31, 2017, essentially uncooked materials and work-in-growth in keeping with the enhance well-known for their products in 2018. accounts payable had been $fifty six.2 million at December 31, 2018, up $8.2 million from its degree at December 31, 2017 because of the raise in raw material purchases. Bel's total fanciful debt turned into reduced with the aid of $744,000 during the fourth quarter, bringing the equilibrium down to $116 million as of December 31, 2018, aside from deferred financing cost.

    ebook cost per share, which is calculated as stockholders' equity divided by artery of their combined A and B classes of timehonored inventory impressive, become $14.39 per partake at December 31, 2018 as in comparison to $13.13 per partake at December 31, 2017. And now i want to point to the cognomen returned to Dan and open the call for questions.

    Dan Bernstein -- President and Chief government Officer

    yes. effect they open up the demand questions, please, Allison? 

    Questions and answers:

    Operator

    actually, sir. [Operator instructions] they are able to now purchase their first question from Sean Hannan from Needham & enterprise. gratify retract ahead, sir.

    Sean Hannan -- Needham and enterprise -- Analyst

    yes. Thanks. respectable morning, everyone. Dan, i used to live looking to behold if I might query you might provide us with a minute bit of detail across the phase.

    i effect know you offered some on your prepared feedback. can you in total probability find into a bit bit extra specificity when it comes to how had been you ardor with each of these section nowadays and the actions they ramp right here within the first quarter and in '19. and perhaps how that may additionally believe trade or could live different versus what you were expecting probably just a brace of months in the past? Any perception there could live very effective. Thanks.

    Dan Bernstein -- President and Chief govt Officer

    adequate. Of path, total of their product businesses and total of the subdivisions inside the product corporations, a majority, i would say, 80% of total were very robust. they now believe one community, is the Modular group and the DC to DC neighborhood out of Italy which believe some tremendous clients that they misplaced, but that hasn't been the rest to effect with the market conditions simply on account of the situation with these clients. So ordinary everything has been, as you live conscious of, extraordinarily fine.

    Going into this quarter and subsequent quarter, January become a very -- they saw a stalwart January, and once again, they suppose they effect not behold any alterations within the first quarter. The handiest concerns that they effect believe is there are some IC businesses that are seeing some softening in the market and they effect hear some rumblings that there may live too a lot inventory in the pipeline. but to this point it has not affected their revenue or backlog. So again, it's why I reckon we're a bit wonderful for the first quarter and for instance, I suppose proximate out after that.

    Sean Hannan -- Needham and company -- Analyst

    adequate. unprejudiced ample. Now as they seem into the power neighborhood, it is definitely always a topic on each and every name. there's a total lot that you've done when it comes to correcting the nice concerns from one of the vital acquisitions you've got taken on, there's a much deal you could believe been doing to step-up executions, plenty that you believe executed in incrementally successful original designs and into original programs some of which has been getting some momentum.

    and that i suppose you said that a bit bit earlier today. What extra may soundless they await within the trajectory of these organizations? Is there the rest within the history that's incrementally being labored down or is obtainable a bogey that might quicken up the boom trajectory that you're now atmosphere into today? Or how should soundless they reckon about how this continue to enhance as a product section for you? Thanks.

    Dan Bernstein -- President and Chief govt Officer

    good enough. So the vigor community, again, as they brought up over the ultimate two or three years, they faith very strongly that has the best boom expertise for Bel from a accurate-line standpoint. On the power, they did believe is after they acquired the company previous administration truly failed to seat of attention on pleasant and customer service. And it took us a very long time to exchange that; a, first change their manufacturing unit then exchange the client opinion, and over the ultimate 18 months, they now believe total their purchasers are back and believe Bel to live a power corporation.

    I feel two issues that they now believe achieved that they now believe changed these days. One became, I consider, as they believe been so desperate for earnings, they took a shotgun approach and really do total inhibit on their R&D community without getting the kind of effects that they would like. So what we've performed is, truly long past from much greater chosen artery of what consumers you exigency to deal with, how they fitting into us and should they live long-time era shoppers? With that said, they are streamlining their R&D community because they will not believe to retract with the southbound method, they comprehend what precisely engineers they deserve to pilot these products as they circulate ahead. the key hardship now could live that they effect believe two or key key customers that may retract anywhere from $eight million to $12 million, $13 million.

    And once we're talking about statistics middle-category of customer, they effect believe much customer classification of valued clientele. again, those fluctuate very much from a earnings standpoint. once more, however, they effect believe that we've located ourselves much more within the market, and currently I feel they now believe 90 NDA signed on high-effectivity vehicles and we're starting to behold that enterprise retract from $three million to $5 million. So we're hoping that would double once more, offers us a lot more diversification, and they are working with different information seat classification of customers.

    So they find that greater assorted. So again, they are soundless taking pictures. Their goal has total the time been to find vigour to that consistent 10% increase over a two to three-12 months period.

    Sean Hannan -- Needham and enterprise -- Analyst

    good enough. that's beneficial. and then closing query right here. just to behold if i will live able to find some standpoint round a customer of yours without retard or ultimately.

    Huawei, I recall you might live now not necessarily even a 5% consumer, but are you able to focus on how effect they play into your enterprise traditionally? And is there the rest that they should soundless reckon of thinking about that relationship or income technology and maybe by some means tied to them on a go-forward groundwork? Thanks.

    Dan Bernstein -- President and Chief executive Officer

    neatly, I suppose, again, being a chinese language business, I believe they are inclined to retract along with chinese providers in China. i know, for instance, they offered their vigor provide neighborhood to Emerson about six years ago, and now former Huawei individuals believe their own vigor give company. So they know it's a troublesome nut to crack. They effect some ICM enterprise, however no longer vast in any respect.

    And for us, it's going to live a stalwart odds as a result of they believe people relish Nortel, Cisco should soundless prefer up the company that they're losing. So i effect know there are certain nations, Czech Republic, even Canada and the U.S. how they view Huawei going ahead. And that they cannot buy rig from Huawei for 5G, they will doubtless retract with -- I failed to value Nortel, I query for forgiveness, Nokia, that Nokia and Cisco will likely elect up that slack and might live Alcatel, and these multinational non-chinese language purchasers they effect much quantity of business with them.

    So we're hoping that their business should soundless increase as more and more 5G is delivered.

    Sean Hannan -- Needham and company -- Analyst

    Very first rate. Thanks so tons, folks.

    Operator

    [Operator instructions] And they will now purchase a question from Hendi Susanto from G. analysis. gratify retract forward.

    Hendi Susanto -- G. analysis -- Analyst

    first rate morning. Dan, you commute to China a much deal. How effect you signify your China market now? How different is it in comparison to a typical 12 months?

    Dan Bernstein -- President and Chief executive Officer

    We at total times -- for us -- total over the realm, I imply, Europe and China there may live so a lot mistrust and how they faith in Donald Trump and the job he's doing. there's giant amount of anxiousness. For us again, for the China market, or not it's always been very intricate to demolish into that market as a result of the pricing parameters that you've got promoting to, again, a chinese language consumer. although, a first-rate component can live 35% of their sales retract to China, but it surely goes throughout the CEM relish the Flextronics or Hon Hai, Foxconn, and those are non-chinese groups.

    youngsters, they effect -- they are starting to behold more americans peek at China in a several easy. They recognize the ODMs in Taiwan, they believe majority of their production in China. They at the second are stirring a few of that creation lower back into Taiwan. They behold other multinationals relocating products round to find across the tariffs.

    So when you've got production in Malaysia, exhaust that for total items coming to the States after which you exhaust your China production to retract into Europe and the a long artery East market. but once again, no one likes mistrust and that without query with the tariffs there's giant amount of uncertainties and that's not first rate for anyone.

    Hendi Susanto -- G. research -- Analyst

    got it. after which Dan, given solid income growth and your backlog boom in 2018 and existing ERP implementation, how a first-rate deal progress in raw margin and working margin they should await in 2019?

    Dan Bernstein -- President and Chief executive Officer

    i will depart that to my accounting neighborhood here.

    Craig Brosious -- vice president of Finance

    yes. I reckon assuming the within your budget sales increase that we're expecting, qualify income increase, I believe they believe some leverage means to movement the raw margin up to maybe a point, aspect and a half. once more, lots of their construction costs are primarily based in the -- in China and counting on which approach the trade agreements go, it may believe an effect on the change fees that they should deal with on the can impregnate of that -- on the labor costs, exceptionally. So barring any massive moves in these change charges, we've opportunities to extend margins a bit bit.

    Hendi Susanto -- G. research -- Analyst

    after which a further question on charge. So I believe Bel Fuse is coping with enhance in labor charge, and that i suppose that has been there for a long time after which you were mitigating or taking movements or improved your labor charge. after they wobble through relish 2019, when can they examine on an apple-to-apple 12 months-over-12 months assessment in regards to the labor can charge? And relish how -- and then live certain you live in a position to quantify how an Awful lot labor impregnate become?

    Craig Brosious -- vice chairman of Finance

    I believe they -- to find to an apples-to-apples comparison, they are able to likely should find within the third quarter of this year because they had impregnate raises going into impact within the first and second quarters of 2018. So I feel as soon as they find to the third quarter, they find some low cost comparatives.

    Lynn Hutkin -- Director of fiscal Reporting

    The most efficacious aspect to add there's, in 2019, we're besides experiencing elevated labor impregnate in Mexico so that you can move the 2019 length, however changed into not there right through the 2018 period. So they believe that as smartly.

    Hendi Susanto -- G. analysis -- Analyst

    adequate. and then the majority of the tariff cost has been passed to clients. can you quantify how a much deal has been handed and what's next?

    Dan Bernstein -- President and Chief executive Officer

    I reckon it's been about $7.eight million, in that latitude.

    Lynn Hutkin -- Director of fiscal Reporting

    In 2018, it become about $2.four million, in total for 2018, in order that become a partial -- that was a partial 12 months.

    Craig Brosious -- vice chairman of Finance

    So relish Dan had mentioned previously, most of their sales as a minimum coming out of China don't become without retard into the U.S. So we're not enormously impacted through the tariffs. So they believe been capable of -- basically $2.5 million or in order that they needed to add.

    Hendi Susanto -- G. analysis -- Analyst

    good enough. acquired it. thanks.

    Operator

    [Operator instructions] It appears there aren't any additional questions. Mr. Bernstein, i would relish to point to the call back to you for any additional or closing remarks.

    Dan Bernstein -- President and Chief govt Officer

    thank you for joining us nowadays, and they seem to talking to you sooner or later. thanks to your time.

    Operator

    [Operator signoff]

    length: 29 minutes

    call members:

    Dan Bernstein -- President and Chief government Officer

    Lynn Hutkin -- Director of monetary Reporting

    Craig Brosious -- vp of Finance

    Sean Hannan -- Needham and enterprise -- Analyst

    Hendi Susanto -- G. research -- Analyst

    greater BELFB analysis

    this article is a transcript of this convention call produced for The Motley fool. while they try for their silly premier, there could live mistakes, omissions, or inaccuracies during this transcript. as with total their articles, The Motley fool does not assume any responsibility for your exhaust of this content material, and they strongly hearten you to effect your personal analysis, together with listening to the call yourself and analyzing the business's SEC filings. gratify behold their phrases and conditions for additional details, together with their mandatory Capitalized Disclaimers of liability.

    10 shares they relish enhanced than Bel FuseWhen investing geniuses David and Tom Gardner believe a stock tip, it can pay to hear. in spite of everything, the e-newsletter they've quicken for over a decade, Motley fool stock marketing consultant, has quadrupled the market.*

    David and Tom simply printed what they coincide with are the 10 finest stocks for investors to buy right now... and Bel Fuse wasn't one in total them! it's appropriate -- they believe these 10 stocks are even more advantageous buys.

    See the ten stocks

    *stock marketing consultant returns as of January 31, 2019

    Motley fool Transcribing has no zone in any of the shares mentioned. The Motley idiot has no position in any of the shares mentioned. The Motley fool has a disclosure policy.


    Bel Fuse Inc. (BELFB) CEO Daniel Bernstein on this autumn 2018 consequences - income cognomen Transcript | killexams.com actual Questions and Pass4sure dumps

    No result discovered, are trying original keyword!Bel Fuse Inc. (NASDAQ:BELFB) this tumble 2018 results profits convention call February 21 ... demand for their vigor substances in diversity of data middle purposes. earnings of their DC to DC and circuit ...

    While it is arduous errand to pick solid certification questions/answers assets regarding review, reputation and validity since individuals find sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets as for exam dumps update and validity. The greater piece of other's sham report objection customers arrive to us for the brain dumps and pass their exams cheerfully and effortlessly. They never compact on their review, reputation and quality because killexams review, killexams reputation and killexams customer conviction is imperative to us. Extraordinarily they deal with killexams.com review, killexams.com reputation, killexams.com sham report grievance, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off desultory that you behold any False report posted by their rivals with the cognomen killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protestation or something relish this, simply recall there are constantly terrible individuals harming reputation of first-rate administrations because of their advantages. There are a much many fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams questions, killexams exam simulator. Visit Killexams.com, their illustration questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.

    Back to Braindumps Menu


    000-137 free pdf | M9560-760 braindumps | TK0-201 brain dumps | OG0-9AB questions and answers | HP2-E15 actual questions | 1Z0-567 practice test | 000-318 pdf download | 00M-230 cheat sheets | CISM mock exam | A2040-956 free pdf download | 650-575 practice Test | 1Z0-547 bootcamp | M2010-719 examcollection | 650-316 practice test | 270-411 free pdf | 77-883 practice test | 1Z0-325 sample test | 1Z0-599 braindumps | 000-913 exam prep | 000-005 practice questions |


    Ensure your success with this 920-106 question bank
    Is it accurate to yell that you are searching for Nortel 920-106 Dumps of actual questions for the NNCSS SYMPOSIUM call seat Exam prep? They give as of late refreshed and incredible 920-106 Dumps. Detail is at http://killexams.com/pass4sure/exam-detail/920-106. They believe gathered a database of 920-106 Dumps from actual exams on the off desultory that you exigency to can enable you to assemble and pass 920-106 exam on the first attempt. Simply set up together their and unwind. You will pass the exam.

    killexams.com tall value 920-106 exam simulator will live facilitating for their customers for the test steering. total vital functions, practice questions and definitions are highlighted in 920-106 brain dumps pdf. Gathering the records in one region will live a actual time saver and makes you confident for the NNCSS SYMPOSIUM call seat exam within a brief time span. The 920-106 exam provides key points. The killexams.com with pass4sure dumps permits to memorize the essential questions or concepts of the 920-106 exam At killexams.com, they present absolutely verified Nortel 920-106 practice questions that are the satisfactory for Passing 920-106 exam, and to induce certified with the assistance of 920-106 braindumps. It is a first-rate option to accelerate your career as a specialist within the Nortel Technology. they are pleased with their quality of supporting humans pass the 920-106 exam of their first attempt. Their success fees at intervals the past 2 years were certain enough gorgeous, because of their delighted shoppers currently ready to boost their career at the quick lane. killexams.com is the primary preference among IT specialists, above total those are trying to climb up the hierarchy of qualifications faster in their respective organization. Nortel is the enterprise leader in info generation, and obtaining certified will live assured to succeed with IT careers. they believe an approach to assist you with their inordinate best Nortel 920-106 brain dumps.

    killexams.com helps millions of candidates pass the exams and find their certifications. They believe thousands of successful reviews. Their dumps are reliable, affordable, updated and of really best quality to overcome the difficulties of any IT certifications. killexams.com exam dumps are latest updated in highly outclass manner on regular basis and material is released periodically. Latest killexams.com dumps are available in testing centers with whom they are maintaining their relationship to find latest material.

    The killexams.com exam questions for 920-106 NNCSS SYMPOSIUM call seat exam is mainly based on two accessible formats, PDF and practice questions. PDF file carries total the exam questions, answers which makes your preparation easier. While the practice questions are the complimentary feature in the exam product. Which helps to self-assess your progress. The evaluation implement besides questions your decrepit areas, where you exigency to do more efforts so that you can help total your concerns.

    killexams.com recommend you to must try its free demo, you will notice the intuitive UI and besides you will find it very smooth to customize the preparation mode. But compose certain that, the actual 920-106 product has more features than the tribulation version. If, you are contented with its demo then you can purchase the actual 920-106 exam product. Avail 3 months Free updates upon purchase of 920-106 NNCSS SYMPOSIUM call seat Exam questions. killexams.com offers you three months free update upon acquisition of 920-106 NNCSS SYMPOSIUM call seat exam questions. Their expert team is always available at back cease who updates the content as and when required.

    killexams.com Huge Discount Coupons and Promo Codes are as under;
    WC2017 : 60% Discount Coupon for total exams on website
    PROF17 : 10% Discount Coupon for Orders greater than $69
    DEAL17 : 15% Discount Coupon for Orders greater than $99
    DECSPECIAL : 10% Special Discount Coupon for total Orders


    920-106 Practice Test | 920-106 examcollection | 920-106 VCE | 920-106 study guide | 920-106 practice exam | 920-106 cram


    Killexams LOT-803 practice test | Killexams C9010-262 questions answers | Killexams 9A0-381 sample test | Killexams 000-918 actual questions | Killexams P2170-035 exam prep | Killexams MSC-321 study guide | Killexams C2090-603 exam prep | Killexams 1Z0-932 cram | Killexams 310-875 practice questions | Killexams CWNA-107 questions and answers | Killexams 1Z0-439 practice exam | Killexams 000-651 pdf download | Killexams NCPT actual questions | Killexams 000-451 practice test | Killexams MSC-331 questions and answers | Killexams ST0-086 examcollection | Killexams 1Z0-100 actual questions | Killexams HP2-H65 practice test | Killexams 70-565-VB bootcamp | Killexams 000-N19 test questions |


    killexams.com huge List of Exam Study Guides

    View Complete list of Killexams.com Brain dumps


    Killexams HP2-E46 free pdf | Killexams SK0-004 actual questions | Killexams HP0-092 practice test | Killexams 00M-194 pdf download | Killexams 000-208 practice questions | Killexams APA-CPP study guide | Killexams 050-644 test prep | Killexams HP2-E15 dumps questions | Killexams MB2-527 practice Test | Killexams HP2-B121 examcollection | Killexams P2170-036 questions and answers | Killexams 3I0-012 test prep | Killexams C2090-625 free pdf | Killexams 700-270 practice questions | Killexams MOS-A2K cheat sheets | Killexams 310-065 exam questions | Killexams 000-976 cram | Killexams PCCE test prep | Killexams LOT-915 practice exam | Killexams 050-CSEDLPS test questions |


    NNCSS SYMPOSIUM call CENTER

    Pass 4 certain 920-106 dumps | Killexams.com 920-106 actual questions | https://www.textbookw.com/

    Strongbridge Biopharma plc (SBBP) Q4 2018 Earnings Conference call Transcript | killexams.com actual questions and Pass4sure dumps

    Logo of jester cap with thought bubble.

    Image source: The Motley Fool.

    Strongbridge Biopharma plc  (NASDAQ:SBBP)Q4 2018 Earnings Conference CallFeb. 26, 2019, 8:30 a.m. ET

    Contents:
  • Prepared Remarks
  • Questions and Answers
  • Call Participants
  • Prepared Remarks:

    Operator

    Good morning, ladies and gentlemen, and welcome to the Strongbridge Biopharma Corporate Update and Fourth Quarter 2018 Earnings Conference Call. At this time, total participants are in a listen-only mode. Later they will conduct a question-and-answer session and instructions will ensue at that time. (Operator Instructions) As a reminder, this call will live recorded.

    I would now relish to interlard your host for today's conference, Ms. Lindsay Rocco of Elixir Health Public Relations. You now may begin.

    Lindsay Rocco -- Investor Relations

    Thank you and first-rate morning, everyone. They are pleased that you could relate us today for Strongbridge Biopharma's fourth quarter and complete year 2018 earnings conference call. Joining me from Strongbridge this morning are Matthew Pauls, President and Chief Executive Officer; Dr. Fred Cohen, Chief Medical Officer; and Brian Davis, Chief pecuniary Officer.

    Before they begin, I would relish to remind you that during this call, the Company will live making forward-looking statements that are topic to risks and uncertainties that may antecedent actual results to disagree from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the Company's periodic and current event filings with the U.S. Securities and Exchange Commission.

    In addition, this presentation includes non-GAAP pecuniary measures. This presentation is not intended to live a substitute for pecuniary results presented in conformity with generally accepted accounting principles in the U.S. Investors and potential investors are encouraged to review the reconciliation of the pro forma pecuniary measures included in the Company's earnings release. The most directly comparable GAAP information and a reconciliation between the non-GAAP and GAAP figures are included in the Company's fourth quarter 2018 earnings release, which has been furnished on form 8-K.

    I will now rotate the call over to Matthew Pauls.

    Matthew Pauls -- President and Chief Executive Officer

    Thank you, Lindsay. first-rate morning everyone and thanks for joining us. For today's call, I'll initiate by providing a brief summary of their fourth quarter and complete year 2018 highlights and results. And then we'll rotate the call over to Dr. Fred Cohen, their Chief Medical Officer, to dispute the ongoing phase III clinical progress program for RECORLEV. Brian Davis, their Chief pecuniary Officer, will then provide a pecuniary overview. They will then open up the call for questions.

    With that, let me start by motto that Strongbridge had a stalwart fourth quarter from a clinical, commercial and pecuniary perspective, which is a reflection of their momentum and overall success throughout the past year. As you will hear from the team today, their accomplishments in 2018 demonstrate the value of their rare disease strategy and believe positioned us for future growth as they continue to identify, develop and commercialize principal treatments for rare diseases. Leveraging the momentum from ultimate year, they entered 2019 with a focus on progressing the progress of RECORLEV for the treatment of endogenous Cushing's syndrome.

    And getting into their most notable fourth quarter accomplishments, let's start with the Novo Nordisk transactions. In December, they significantly strengthened their equilibrium sheet with the sale of the U.S. and Canadian rights of MACRILEN to Novo Nordisk. As previously mentioned, a portion of the upfront cash payment of $145 million from Novo Nordisk to Strongbridge was used to repay total outstanding debt. Other key terms from the transaction comprehend that Strongbridge will receive royalties on MACRILEN sales through 2027. And in addition, Novo Nordisk purchased 5.2 million ordinary shares of Strongbridge at a purchase expense of $7 per share, resulting in raw proceeds of $36.7 million.

    Another principal key strategic term of the transaction is that Novo Nordisk will fund Strongbridge's 23-person rare endocrine commercial field organization over the next three years to promote MACRILEN in the United States. This aligns with the Company's objective to maximize the potential of MACRILEN, while preparing for the potential regulatory approval of RECORLEV in endogenous Cushing's syndrome, a rare condition that's often treated by the identical endocrinologist that diagnose and deal adult growth hormone deficiency.

    Onto their rare neuromuscular franchise. KEVEYIS, their first commercial product, enabled us to build out a rare neuromuscular franchise, which continues to live a strategic pillar for the Company. They are committed to serving the needs of the primary periodic paralysis, or PPP community, which is comprised of an estimated 4,000 to 5,000 currently diagnosed patients in the United States. As they prepare for the regulatory filing of potential launch of RECORLEV, there are many parallels and learnings that they believe garnered from the KEVEYIS opening that they believe and will continue to leverage across their business.

    Additionally, they believe that the experience and lore gained from launching KEVEYIS best positioned Strongbridge to acquire the rights to MACRILEN early ultimate year, before selling the rights to Novo Nordisk at the cease of the year. As piece of their life cycle management planning for KEVEYIS, they are executing on a number of initiatives with the primary objective of maximizing the value of KEVEYIS over time. They believe that by the cease of 2019 or into early 2020 that they will live in a position to provide an update on their life cycle management progress.

    Our investment approach with KEVEYIS focuses on three key areas. Specifically, they are focusing their KEVEYIS commercial investment on, one, utilizing sophisticated data to identify physicians that deal PPP; two, fully leveraging their CareConnection patient services model; and three, engaging the PPP community through both patient advocacy, as well as targeted sociable media. They peek forward to executing against their 2019 plans and believe that KEVEYIS will generate a positive contribution margin by the cease of the first quarter of 2020.

    So with that I'll rotate the call over to Dr. Fred Cohen, their Chief Medical Officer, to dispute their clinical progress progress for RECORLEV, which they believe continues to believe the potential to live a first-line, first-choice therapy for patients with endogenous Cushing's syndrome.

    I will now rotate the call over to Fred.

    Fredric Cohen -- Chief Medical Officer

    Thank you, Matt. first-rate morning, everyone. As previously announced in the third quarter, the pivotal phase III SONICS study of RECORLEV for the treatment of endogenous Cushing's syndrome met its primary endpoint, with urinary free cortisol or UFC confirmed (ph) as timehonored among 30% of the intent to deal population at the cease of the six-month maintenance phase.

    Detailed initial results from the SONICS study were presented in October at the European NeuroEndocrine Association Annual Meeting, with additional data presented at the European Network for the study of Adrenal Tumors Annual Meeting in November. These analyses illustrated the conducive effects of RECORLEV on hypercortisolism and its comorbidities, particularly sustained improvements in markers of cardiovascular risk, such as LDL-cholesterol, hemoglobin A1C and carcass weight.

    Further SONICS results from the cease of maintenance analyses are planned for presentation at the International Pituitary Congress and the Endocrine Society's Annual Meetings in late March, and at the American Association of Clinical Endocrinology Meeting in April. These results will highlight additional benefits of RECORLEV on the signs and symptoms of hypercortisolism.

    Additionally, submission of a manuscript of the primary efficacy and safety data from SONICS to a peer-reviewed journal is anticipated in the first half of 2019. One-year data from the completed SONICS study are expected to live available in the first half of 2019. These data will comprehend findings from the six-month extended evaluation phase, which is primarily intended to characterize the long-term safety, tolerability and benefit-risk profile of RECORLEV.

    From a regulatory standpoint, a kind C meeting with the FDA is planned within this quarter to seek guidance on the path forward to obtain marketing approval for RECORLEV in the United States, and that process is on track. They anticipate providing an update in the second quarter.

    Finally, the receipt of top line results from the phase III LOGICS study remains on track for the fourth quarter of 2019. As a reminder, LOGICS is a double blind tribulation with no planned interim analyses prior to the receipt of these anticipated results.

    And with that, I will now rotate the call over to Brian Davis for a pecuniary overview.

    A. Brian Davis -- Chief pecuniary Officer

    Thank you, Fred. Their press release accommodate details of their pecuniary results for the fourth quarter and complete year 2018. Rather than read total of those details, my comments will seat on a few highlights.

    As preeminent in the press release, their guidance for KEVEYIS revenues in 2019 is in the $18 million to $20 million range. They believe significantly improved their pecuniary and strategic flexibility as a result of the cash proceeds and anticipated future payments from their transactions with Novo Nordisk, as well as the repayment in complete of their outstanding debt. They ended 2018 with $122.5 million of cash, cash equivalents and no outstanding debt. As for cash runway, they believe the combination of their existing cash resources, anticipated KEVEYIS revenues and payments from Novo Nordisk, as well as the continued prudent management of their operating expenses will provide sufficient capital to back their operations, at least through the first quarter of 2021.

    And Catherine, with that, they are now ready to open up the call for questions.

    Questions and Answers:

    Operator

    (Operator Instructions) And their first question comes from Esther Hong with Janney. Your line is open.

    Esther Hong -- Janney -- Analyst

    Hi, first-rate morning. Thanks for taking my questions. So with respect to the kind C FDA meeting over RECORLEV, can you provide additional details on your expectations, and then, any potential logistics regarding accelerator approval? And then the second question is, any updates on business progress plans in 2019? Thanks.

    Matthew Pauls -- President and Chief Executive Officer

    So Esther, this is Matt. Thank you for the questions. Let me purchase them in transpose order. With admiration to business development, they obviously don't comment on any business development-related projects that they may live working on. I effect believe that their history here at Strongbridge -- as they continue to build the Company is that they are vigorous in looking at opportunities and that continues. And that's total I'll yell on that front. I will believe Dr. Cohen comment on the kind C regulatory process and timing.

    Fredric Cohen -- Chief Medical Officer

    Sure. So as I've just -- they effect blueprint to believe the discussion with the FDA in the first quarter of this year, and then following digestion of that and then any clarifying dialog they exigency to believe with the FDA, they blueprint to update investors by the second quarter with the path forward, as they said. In terms of their basis case, just to reiterate, they are anticipating that the FDA will pilot us toward the exigency for both the complete SONICS as well as the complete LOGICS study for being in hand and included within NDA. Again, that's the basis case. The upside case for us that they believe is supported with the unmet medical need, the artery that SONICS was designed in terms of using a surrogate endpoint that's been established, and the precedent within this division of allowing approval on the basis of the lone open label study, they believe that there is an upside case where there could live an accelerated pathway toward the filing, where they basis it primarily just on the SONICS, to your point around accelerator approval. Again, they effect believe that the dialog that we're anticipating with the FDA in this quarter will compose that pathway limpid for us and then we'll update you guys accordingly.

    And with admiration to timing, that's just so -- in the expedited or accelerated upside case, clearly they would live working arduous to find it -- find the NDA filed as quickly as possible, probably realistically why they would cherish to believe it filed by the cease of the year, at the cease of 2019, it probably would live more relish an early 2020-ish. More details to arrive on that, obviously, as they believe more clarity. In the basis case, it would live about a year later than that. I hope that helps.

    Esther Hong -- Janney -- Analyst

    It does. Great, thank you.

    Fredric Cohen -- Chief Medical Officer

    You are welcome.

    Operator

    Thank you. And their next question comes from Annabel Samimy with Stifel. Your line is open.

    Nick Rubino -- Stifel -- Analyst

    Good morning, everyone. This is Nick Rubino on for Annabel Samimy. Thanks for taking their question. First, how the efforts to educate physicians on titration helped patient retention. Are you soundless seeing attrition due to the side effects and how effect you behold those dynamics playing out 2019 and beyond? And then second with the one-year SONICS, you had mentioned the safety pieces, but are they getting efficacy measures as well? And then, if I can just sneak in a quick rapid one, with the MACRILEN revenue numbers you reported this quarter, are those purely royalty revenues or did those comprehend complete sales from October and November? Thanks.

    Matthew Pauls -- President and Chief Executive Officer

    Thanks for those questions, Nick. Let me give you a minute insight on the first question regarding KEVEYIS. They learned a lot on the KEVEYIS fronts in 2018 regarding both KEVEYIS as well as primary periodic paralysis. And one of the key learnings which you well said was around the need, often to retract a minute bit lower and a minute bit slower in the titration period. And, I'll query Dr. Cohen just to comment briefly on that. I think, they believe some learnings from phase III tribulation and then from the clinical -- not just clinical instant -- in the clinical trial, but besides in the commercial exhaust too. So, Fred, effect you want to comment on that?

    Fredric Cohen -- Chief Medical Officer

    Yeah. Yeah, sure. Great. So one of the things that they learned was that there are a significant minority of patients who experienced adverse reactions from the drug early on in the therapy. And one of them -- one of those reactions that's common is on -- a confusion on mental fog, if you will, that occurs. It's a fleeting response to the drug until the brain can sort of equilibrate and become used to the drug. But when it occurs, it needs to live addressed, it needs to live managed, and the best artery that they know how to manage it is by lowering the dose of the drug.

    Well, it took us a while, I think, number one, to recognize that this was a reaction that was accountable for some patients discontinuing from the drug. And once they did recognize that, they do in zone a chain of educational efforts aimed at physicians initially and then later direct-to-patient education and keeping through the exhaust of, for example, patient ambassadors that believe given their time generously to profit educate other patients. And so we're making much progress. I think, it's unprejudiced to yell we've seen already changes in the artery the titrations are going. And we've gotten feedback from patients who are now able to overcome the initial side-effects and believe stayed on the drug, because they are seeing benefits from it in many cases. So, I hope that addresses that piece of that question.

    Nick Rubino -- Stifel -- Analyst

    Yes, that's great. Then, with regards to the --

    Matthew Pauls -- President and Chief Executive Officer

    Yes, the MACRILEN revenues during the fourth quarter were product sales by Strongbridge. There were no royalties in their revenues for the quarter.

    Fredric Cohen -- Chief Medical Officer

    Yes, there was besides a question you had about the 1-year RECORLEV data. So on the top line data that they will live sharing with you will comprehend primarily safety data. But besides they did measure some efficacy data as well, including urine free cortisol, as well as those comorbidity markers. And I'm pretty certain we'll live sharing that with you at the time they release the top line results.

    Nick Rubino -- Stifel -- Analyst

    Alright. Great. Thank you guys.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, thanks for the questions.

    Operator

    Thank you. And their next question comes from Hartaj Singh with Oppenheimer & Company. Your line is open.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great, thanks. Thanks for the question and a first-rate year. Just a brace of questions, Matt I've got. On your interactions with the FDA prior to this meeting, I assume you might believe already submitted a sort of a briefing package and kindly of there believe been some interactions back and forth. Can you just give some color on, sort of, the gist of those interactions and what are some of the questions that maybe you're asking or FDA is wanting to live addressed prior to the actual meeting? And then a second question, just on KEVEYIS, to ensue up with the previous question. Matt, can you just give some color on, sort of, original patients, continuing patients, what sort of -- how many patients are staying on drug, on average, just any color around what that dynamic is, because it seems that the drug is growing quarter-on-quarter. And then just your thoughts about that going forward. And then just a quick housekeeping question after that. Thank you.

    Matthew Pauls -- President and Chief Executive Officer

    Great, thank you Hartaj. So on the regulatory question related to RECORLEV. As a standard course for us, they don't comment on the interactions prior to having their final interpretation of the dialog. So more to arrive in the second quarter. And I think, Fred articulated well earlier what their basis case assumptions are meeting both trials and the upside case around an accelerated potential approval, given the significant unmet exigency in Cushing syndrome, UFC being a stated accepted surrogate endpoint by the FDA, resoundingly positive, and they believe compelling SONICS data. And then, in this division, in the review of Cushing's syndrome, lone tribulation approvals. So that's where we're at and we'll provide an update in the second quarter.

    And then with admiration to KEVEYIS -- and your question on KEVEYIS. So what they know is that there -- they are confident there are 4,000 to 5,000 patients currently diagnosed with PPP. They are seeing original patients regularly arrive onto KEVEYIS. And they are doing a much better job, as Fred mentioned, with admiration to patient-to-patient interaction, patient-to-physician interaction, recommendations around maybe lower and slower titration or down titration. So they are seeing patients more often than not -- now remain on the drug through that kindly of an interim period.

    And so, the much focus for us here is being smart and choiceful about their investment smooth with admiration to KEVEYIS, because it's principal for many reasons to try to drive KEVEYIS to profitability on a stand-alone basis as quickly as possible. And we're confident that we're on that path by the cease of the first quarter of 2020. And parallel to that, given the fact that there are no other drugs really that are in progress for the treatment of this ultra-rare genetic neuromuscular condition, PPP, they are working very feverishly and hard, as we've said previously, around life cycle management opportunities. They would cherish to believe the opening to believe more runway with KEVEYIS. So more to arrive by the -- probably by the cease of the year, again, maybe into 2020 on their life cycle management plans. But this is a market that prior to us relaunching the drug really had no investment ever, was disorganized, unstructured. And we're confident that we're on the path to structuring it, organizing it and getting KEVEYIS to profitability, so that we're being smart and choiceful and sane with admiration to their investment.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great. And Matt, that's much color. Just a follow-up on that. So roughly speaking, are you sort of seeing patients that are coming that are original to KEVEYIS being equal to patients dropping off, or is there less of a drop-off, just what's the dynamic there between the original and the continuing patients and the patients that are leaving, whether it's titration or for other issues?

    Matthew Pauls -- President and Chief Executive Officer

    So, they -- the trend is that more patients are staying on the drug than off. And that's based on the interventions, really in -- I guess in the back half of the third quarter and the fourth quarter by us, and of course to-date. So what we're -- the patient identification and identifying patients who are very motivated and physicians that are motivated and then providing the very stalwart smooth of back and service for them through that process, given the potency of KEVEYIS. I value the drug really works. It really works. They are having success getting patients through that short -- I don't know -- for a four-to-six-week period-ish, that range. But it's upwards of eight weeks.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Got it. And then just one housekeeping question on -- just how to believe about operating expenditures, sort of, going forward for the year, just any thoughts there? And again, thank you so very much.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, Hartaj. This is Brian, Hartaj. Thanks for that. So, on the cash basis, as I mentioned, we're looking at a runway that takes us through the first quarter of 2021. I believe they believe the profit of the Novo Nordisk subsidy coming online here in 2019 to offset the commercial exertion around MACRILEN. And so we'll believe a minute transition working through Q1 to find down on a cash scorch basis. But they feel pretty restful in that low-to-mid teens zone as they wobble forward. In fact, if you purchase that $122 million cash equilibrium and just by simple averaging over the subsequent nine quarters through the first quarter of 2021 that comes up to about $13.5 million. So a minute more in this year, reflecting the transition down, reflecting we've got some increased RECORLEV program expenses (inaudible) tall water mark, if you will, for the RECORLEV program, because they believe SONICS and LOGICS and OPTICS running simultaneously, but obviously SONICS expense is winding down now that the one-year data will live coming through. So again, enough cash to find us at least through the first quarter. And obviously, we'll believe more definition on that as they retract along as to how much more at least it can be.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great. And I really cherish it. Thank you very much.

    Operator

    Thank you. And their next question comes from Liisa Bayko with JMP Securities. Your line is open.

    Liisa Bayko -- JMP Securities -- Analyst

    Hi, congratulations on the quarter. Just a brace of questions for me, mainly about KEVEYIS. So first of all, I want to yell congratulations, I value you've made this into a product that reached $20 million this year, which is certainly a lot higher than where you thought the product brace of years ago. They technically were only talking about $1 million. So it's obvious that you've done a tremendous job in creating this market. But again (ph) your guidance a minute bit, for this year, looks relish $4.4 million is the kindly of what you're coming off 4Q (ph). Your guidance of $18 million to $20 million implies a minute bit of slowing growth. So is that -- are patients adds soundless happening at the identical rate or is that lower, are you having -- struggling to find more patients or is it based on -- basically from your comments, I'm thinking maybe less revenue per patient because of dose titration. What's the kindly of dynamic with add indications or revenue per patient? How does that -- what's sort of underlying the guidance?

    A. Brian Davis -- Chief pecuniary Officer

    Yes, this is Brian. So again, we're continuing the first-rate news, is find patients. And they feel really first-rate about the field obligate they believe in zone and they're performing very strongly, as Matt indicated in his comments and in the prior answer. We've had a lot of learning in this market and working through how best not only to attract patients, but besides to retain patients. So they were conscious of the revenue ambit that they do out there, $18 million to $20 million and where we've arrive off of this year, we're going to live conservative in their approach, But the patient retention piece takes time and they believe we're working through it.

    On the expense side, they believe focused their investment and made decisions to dwindle the territories to profit compose certain they find to a positive contribution margin or a profitability standpoint for the product. They went from 21 down to 17 territories. They focused their marketing expenses to those -- really targeted toward the patient, in order to profit total of the revenue expenses to line up. So, we'll hold working through it, but they feel first-rate about their capacity to not only hit this range, but besides to find this product to live one that's a profitable one. And as you pointed out at the beginning, it was a very challenging market to enter into. You're quite correct. Before they had acquired the drugs -- the drug, I should say, its sales had been less than $1 million in a year. So, yes.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, so Liisa, the other piece on that to note is, as I mentioned, in parallel, they are looking at life cycle management opportunities and we'll update the market probably by the cease of the year or in early 2020. And if there are potential opportunities to extend the life and runway of KEVEYIS, they will obviously, probably revisit their investment strategy with admiration to the brand. But right now, it is to find it to profitability as quickly as viable and to grow the top line, which they will effect both. And exiting the year, the low cease of the range, we're tracking already to the low cease of the range. So hopefully, there will live some -- even more enhanced or increased momentum as they retract the year.

    Liisa Bayko -- JMP Securities -- Analyst

    Okay, unprejudiced enough. And then, I guess, as you peek longer-term, are you soundless thinking this product is kindly of easily a brace hundred million or effect you believe some other kindly of target in intellect longer-term now that you've had more experience selling the drug? Just thinking about how, kindly of, directionally where they should live headed in terms of modeling. Thanks.

    A. Brian Davis -- Chief pecuniary Officer

    I believe -- this is Brian. I think, there's a brace of things there, Liisa, that really play into that. So one is the patient penetration. So they believe we've got an opening and we're really just at the nascence stages of it in terms of patient penetration. Now Matt and Fred were taking a minute bit earlier about life cycle management opportunities, having a longer commercial runway will certainly allow us the opening to achieve peak sales levels over a longer era of time that they believe (inaudible). We're just operating with the current regulatory exclusivity. I think, the other piece that obviously plays into in this environment is around the expense of the drug. And I would note, they continue to live very cautious in their thinking around that. So we'll talk about pricing strategy, specifically, but we're very conscious of the environment that we're in and we're going to act appropriately in that environment, and really try to effect total they can to compose certain patients -- as many patients believe access to the drug as viable over time. But they believe there's a longer runway in terms of reaching out to patients and life cycle management opportunities would certainly profit to find us up to higher peak sales levels.

    Liisa Bayko -- JMP Securities -- Analyst

    Okay. Thank you very much for your comments. cherish it.

    A. Brian Davis -- Chief pecuniary Officer

    Thanks Liisa.

    Operator

    Thank you. And I'm showing no further questions at this time. I'd relish to rotate the call back to Mr. Matthew Pauls for any closing remarks.

    Matthew Pauls -- President and Chief Executive Officer

    Thank you. In summary, these fourth quarter and complete year 2018 results underscore that their strategy, their assets, their people, their capital and their infrastructure well position us for continued success in 2019 and beyond. Thank you for joining today's call and for your continued support.

    Operator

    Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may total disconnect. Everyone believe a much day.

    Duration: 33 minutes

    Call participants:

    Lindsay Rocco -- Investor Relations

    Matthew Pauls -- President and Chief Executive Officer

    Fredric Cohen -- Chief Medical Officer

    A. Brian Davis -- Chief pecuniary Officer

    Esther Hong -- Janney -- Analyst

    Nick Rubino -- Stifel -- Analyst

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Liisa Bayko -- JMP Securities -- Analyst

    More SBBP analysis

    Transcript powered by AlphaStreet

    This article is a transcript of this conference call produced for The Motley Fool. While they strive for their silly Best, there may live errors, omissions, or inaccuracies in this transcript. As with total their articles, The Motley Fool does not assume any responsibility for your exhaust of this content, and they strongly hearten you to effect your own research, including listening to the call yourself and reading the company's SEC filings. gratify behold their Terms and Conditions for additional details, including their Obligatory Capitalized Disclaimers of Liability.

    Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


    Nektar Therapeutics to Webcast Conference call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium | killexams.com actual questions and Pass4sure dumps

    SAN FRANCISCO, Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, Dr. Adi Diab, and company management on Friday, March 1, 2019 at 3:00 p.m. Pacific Time during the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The event will ensue Friday's oral presentation by Dr. Diab of preliminary data from the ongoing dose-escalation stage of the betray phase 1/2 clinical study evaluating the combination of TLR agonist, NKTR-262, with a CD122-preferential IL-2 pathway agonist, bempegaldesleukin* (NKTR-214), in patients with locally advanced or metastatic solid tumors.

    Details on the Analyst Call:

    Date and Time: Friday, March 1, 2019 at 3:00 p.m. Pacific Time

    Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (international)

    Passcode: 6970019

    The conference call will include lead investigator on the betray study, Dr. Adi Diab, aide Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center. The webcast and slides for the conference call can live accessed through a link that is posted on the Investors section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. The event will besides live available for replay for two weeks on the company's website, www.nektar.com.

    Details on the Oral Presentation at ASCO-SITC:

    Abstract Title: "Phase Ib: preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 

    agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid

    tumors (REVEAL phase Ib/II Trial)"

    Abstract: #28

    Presenter: Dr. Adi Diab, MD Anderson Cancer Center

    Session: Oral Abstract Session B

    Date and Time: Friday, March 1, 2019, 1:00 p.m.-2:15 p.m. Pacific Time

    About NektarNektar Therapeutics is a research-based, progress stage biopharmaceutical company whose mission is to ascertain and develop innovative medicines to address the unmet medical needs of patients. Their R&D pipeline of original investigational medicines includes treatments for cancer, auto-immune disease and confirmed pain. They leverage Nektar's proprietary and proven chemistry platform in the discovery and design of their original therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug progress programs and capabilities may live organize online at www.nektar.com.

    * rINN (recommended International Nonproprietary Name)

     

    View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-webcast-conference-call-for-analysts-and-investors-at-the-2019-asco-sitc-clinical-immuno-oncology-symposium-300801596.html


    American Outdoor Brands Corporation® Third Quarter Fiscal 2019 pecuniary Release and Conference call Alert | killexams.com actual questions and Pass4sure dumps

    SPRINGFIELD, Mass., Feb. 22, 2019 /PRNewswire/ -- American Outdoor Brands Corporation (nasdaq global select:AOBC) today announced that it plans to release its third quarter fiscal 2019 pecuniary results on Thursday, March 7, 2019, after the proximate of the market. The complete text of the press release will live available on the American Outdoor Brands web site at www.aob.com under the Investor Relations section.

    The company will host a conference call and webcast on March 7, 2019, to dispute its third quarter fiscal 2019 pecuniary and operational results. Speakers on the conference call will comprehend James Debney, President and Chief Executive Officer, and Jeffrey D. Buchanan, Executive Vice President and Chief pecuniary Officer. The conference call may comprehend forward-looking statements. The conference call and webcast will initiate at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Those interested in listening to the conference call via telephone may call directly at (844) 309-6568 and reference conference identification number 9683518. No RSVP is necessary. The conference call audio webcast can besides live accessed live and for replay on the company's website at www.aob.com, under the Investor Relations section. The company will maintain an audio replay of this conference call on its website for a era of time after the call. No other audio replay will live available.

    About American Outdoor Brands Corporation American Outdoor Brands Corporation (nasdaq global select:AOBC) is a provider of quality products for shooting, hunting, and rugged outdoor enthusiasts in the global consumer and professional markets. The Company reports two segments: Firearms and Outdoor Products & Accessories. Firearms manufactures handgun long gun, and suppressor products sold under the Smith & Wesson®, M&P®, Thompson/Center Arms™, and Gemtech® brands, as well as provides forging, machining, and precision plastic injection molding services. AOB Outdoor Products & Accessories is the industry leading provider of shooting, reloading, gunsmithing, gun cleaning supplies, specialty tools and cutlery, and electro-optics products and technology for firearms. They bear innovative, top quality products under the brands Caldwell®; Wheeler®; Tipton®; Frankford Arsenal®; Lockdown®; BOG®; Hooyman®; Smith & Wesson® Accessories; M&P® Accessories; Thompson/Center Arms™ Accessories; Schrade®; ragged Timer®; Uncle Henry®; Imperial®; BUBBA®; UST®;  Lasergrips®, Laserguard®, LiNQ®, Lightguard®, Defender Series™, Rail Master®, and LaserLyte.  For more information on American Outdoor Brands Corporation, call (844) 363-5386 or log on to www.aob.com.  

    Contacts:Liz Sharp, VP Investor RelationsAmerican Outdoor Brands Corporation(413) 747-6284lsharp@aob.com

    View original content to download multimedia:http://www.prnewswire.com/news-releases/american-outdoor-brands-corporation-third-quarter-fiscal-2019-financial-release-and-conference-call-alert-300800591.html

    SOURCE American Outdoor Brands Corporation

    Copyright (C) 2019 PR Newswire. total rights reserved



    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [48 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [13 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [750 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1532 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [64 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [374 Certification Exam(s) ]
    Mile2 [3 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [39 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [279 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [12 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]





    References :


    Dropmark : http://killexams.dropmark.com/367904/11788593
    Wordpress : http://wp.me/p7SJ6L-1FZ
    Dropmark-Text : http://killexams.dropmark.com/367904/12550696
    Blogspot : http://killexamsbraindump.blogspot.com/2017/12/free-pass4sure-920-106-question-bank.html
    RSS Feed : http://feeds.feedburner.com/EnsureYourSuccessWithThis920-106QuestionBank
    Box.net : https://app.box.com/s/v3e63p1mihwq6ygnznh96frr77zwlpp6











    Killexams 920-106 exams | Killexams 920-106 cert | Pass4Sure 920-106 questions | Pass4sure 920-106 | pass-guaratee 920-106 | best 920-106 test preparation | best 920-106 training guides | 920-106 examcollection | killexams | killexams 920-106 review | killexams 920-106 legit | kill 920-106 example | kill 920-106 example journalism | kill exams 920-106 reviews | kill exam ripoff report | review 920-106 | review 920-106 quizlet | review 920-106 login | review 920-106 archives | review 920-106 sheet | legitimate 920-106 | legit 920-106 | legitimacy 920-106 | legitimation 920-106 | legit 920-106 check | legitimate 920-106 program | legitimize 920-106 | legitimate 920-106 business | legitimate 920-106 definition | legit 920-106 site | legit online banking | legit 920-106 website | legitimacy 920-106 definition | >pass 4 sure | pass for sure | p4s | pass4sure certification | pass4sure exam | IT certification | IT Exam | 920-106 material provider | pass4sure login | pass4sure 920-106 exams | pass4sure 920-106 reviews | pass4sure aws | pass4sure 920-106 security | pass4sure coupon | pass4sure 920-106 dumps | pass4sure cissp | pass4sure 920-106 braindumps | pass4sure 920-106 test | pass4sure 920-106 torrent | pass4sure 920-106 download | pass4surekey | pass4sure cap | pass4sure free | examsoft | examsoft login | exams | exams free | examsolutions | exams4pilots | examsoft download | exams questions | examslocal | exams practice |



    International Edition Textbooks

    Save huge amounts of cash when you buy international edition textbooks from TEXTBOOKw.com. An international edition is a textbook that has been published outside of the US and can be drastically cheaper than the US edition.

    ** International edition textbooks save students an average of 50% over the prices offered at their college bookstores.

    Highlights > Recent Additions
    Showing Page 1 of 5
    Operations & Process Management: Principles & Practice for Strategic ImpactOperations & Process Management: Principles & Practice for Strategic Impact
    By Nigel Slack, Alistair Jones
    Publisher : Pearson (Feb 2018)
    ISBN10 : 129217613X
    ISBN13 : 9781292176130
    Our ISBN10 : 129217613X
    Our ISBN13 : 9781292176130
    Subject : Business & Economics
    Price : $75.00
    Computer Security: Principles and PracticeComputer Security: Principles and Practice
    By William Stallings, Lawrie Brown
    Publisher : Pearson (Aug 2017)
    ISBN10 : 0134794109
    ISBN13 : 9780134794105
    Our ISBN10 : 1292220619
    Our ISBN13 : 9781292220611
    Subject : Computer Science & Technology
    Price : $65.00
    Urban EconomicsUrban Economics
    By Arthur O’Sullivan
    Publisher : McGraw-Hill (Jan 2018)
    ISBN10 : 126046542X
    ISBN13 : 9781260465426
    Our ISBN10 : 1260084493
    Our ISBN13 : 9781260084498
    Subject : Business & Economics
    Price : $39.00
    Urban EconomicsUrban Economics
    By Arthur O’Sullivan
    Publisher : McGraw-Hill (Jan 2018)
    ISBN10 : 0078021782
    ISBN13 : 9780078021787
    Our ISBN10 : 1260084493
    Our ISBN13 : 9781260084498
    Subject : Business & Economics
    Price : $65.00
    Understanding BusinessUnderstanding Business
    By William G Nickels, James McHugh, Susan McHugh
    Publisher : McGraw-Hill (Feb 2018)
    ISBN10 : 126021110X
    ISBN13 : 9781260211108
    Our ISBN10 : 126009233X
    Our ISBN13 : 9781260092332
    Subject : Business & Economics
    Price : $75.00
    Understanding BusinessUnderstanding Business
    By William Nickels, James McHugh, Susan McHugh
    Publisher : McGraw-Hill (May 2018)
    ISBN10 : 1260682137
    ISBN13 : 9781260682137
    Our ISBN10 : 126009233X
    Our ISBN13 : 9781260092332
    Subject : Business & Economics
    Price : $80.00
    Understanding BusinessUnderstanding Business
    By William Nickels, James McHugh, Susan McHugh
    Publisher : McGraw-Hill (Jan 2018)
    ISBN10 : 1260277143
    ISBN13 : 9781260277142
    Our ISBN10 : 126009233X
    Our ISBN13 : 9781260092332
    Subject : Business & Economics
    Price : $77.00
    Understanding BusinessUnderstanding Business
    By William Nickels, James McHugh, Susan McHugh
    Publisher : McGraw-Hill (Jan 2018)
    ISBN10 : 1259929434
    ISBN13 : 9781259929434
    Our ISBN10 : 126009233X
    Our ISBN13 : 9781260092332
    Subject : Business & Economics
    Price : $76.00
    920-106920-106
    By Peter W. Cardon
    Publisher : McGraw-Hill (Jan 2017)
    ISBN10 : 1260128474
    ISBN13 : 9781260128475
    Our ISBN10 : 1259921883
    Our ISBN13 : 9781259921889
    Subject : Business & Economics, Communication & Media
    Price : $39.00
    920-106920-106
    By Peter Cardon
    Publisher : McGraw-Hill (Feb 2017)
    ISBN10 : 1260147150
    ISBN13 : 9781260147155
    Our ISBN10 : 1259921883
    Our ISBN13 : 9781259921889
    Subject : Business & Economics, Communication & Media
    Price : $64.00
    Result Page : 1 2 3 4 5